BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

  Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

  November 9, 2023

   · 

  13 min read
• Genetown

  Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

  Fulcrum Therapeutics, Inc. today announced that management will participate in the following upcoming investor conferences.

  November 9, 2023

   · 

  1 min read
• Lunit Expands Reach of its AI-Powered Chest Screening Solution to Global Military Health Institutions

  Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced the successful supply of its AI-powered chest screening solution, Lunit INSIGHT CXR, to several key institutions in the Philippines and South Korea military.

  November 9, 2023

   · 

  2 min read
• Drug Development

  Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

  Artax Biopharma, Inc. announces that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted clinical trial authorization to evaluate AX-158 in a Phase 2a psoriasis study.

  November 9, 2023

   · 

  4 min read
• Business

  Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

  Chemomab Therapeutics Ltd. today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate update.

  November 9, 2023

   · 

  10 min read
• Drug Development

  Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

  Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2 trial to evaluate the efficacy and safety of TTX-030, a potential first-in-class, anti-CD39 antibody.

  November 9, 2023

   · 

  2 min read
• Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference

  Ventus Therapeutics announced today that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel 2023 Healthcare Conference in New York.

  November 9, 2023

   · 

  2 min read
• Genetown

  Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

  Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).

  November 9, 2023

   · 

  4 min read
• BioCapital

  Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

  Senseonics Holdings, Inc. today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.

  November 9, 2023

   · 

  1 min read
• Business

  Immunome Reports Third Quarter 2023 Financial Results

  Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

  November 9, 2023

   · 

  10 min read